News & Videos - CARDAX INC. CDXI

Cardax Reports Q3 2019 Results - CHASE clinical trial interim review demonstrated beneficial changes in markers of cardiovascular health - Composition of matter and use patents filed to extend U.S. and worldwide patent coverage to 2039-2040 - ZanthoSyn® sales rebounded -- Q3 2019 sales five times Q2 2019, with return to normal inventory sell-in patterns - $1,390,000 raised since beginning of Q3 2019 to date PR Newswire HONOLULU, Nov. 14, 2019 HONOLULU , Nov. 14, 2019 /PRNewswire/ -- Cardax,...

Cardax Announces Interim Results from CHASE Clinical Trial Pre-Specified Interim Review Demonstrated Beneficial Changes in Markers of Cardiovascular Health - CRP, LDL, total cholesterol, triglycerides, oxidized LDL, and blood pressure reduced - Interim results support excellent safety profile - Enrollment continues PR Newswire HONOLULU, Sept. 23, 2019 HONOLULU , Sept. 23, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) today announced results from the pre-specified interim review of its ongoing...

Cardax Reports Q2 2019 Results - CHASE clinical trial progressing; interim review planned for September 2019 - $1,675,000 raised since beginning of Q2 2019 - ZanthoSyn® sell-through strong; top selling antioxidant nationwide at GNC in 2019 - ZanthoSyn® sell-in down in Q2 2019 but has increased in Q3 2019 - ZanthoSyn® retail expansion beyond GNC planned PR Newswire HONOLULU, Aug. 14, 2019 HONOLULU , Aug. 14, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) today filed its Quarterly Report on...

Cardax Files Registration Statement for Proposed $15 Million Follow-On Offering - Maxim Group to serve as sole book running manager on a firm commitment basis - Funds to be used primarily for pharmaceutical development - Concurrent Nasdaq uplisting planned PR Newswire HONOLULU, Aug. 14, 2019 HONOLULU , Aug. 14, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today that it filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed...

Cardax Reports Q1 2019 Results PR Newswire HONOLULU, May 17, 2019 HONOLULU , May 17, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced results for the quarter ended March 31, 2019 , in its Quarterly Report on Form 10-Q filed May 15, 2019 with the SEC. Cardax continued to make progress in Q1 2019 across its primary areas of focus: the ZanthoSyn® consumer health business, CHASE human clinical trial, and Rx development programs. ZanthoSyn® Sales : Q1 2019 represented the top performing...

Cardax Reports 2018 Results - Revenues More Than Doubled - CHASE Clinical Trial Initiated - Rx Development Plans for CDX-101 and CDX-301 Underway PR Newswire HONOLULU, March 28, 2019 HONOLULU , March 28, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced results for the year ended December 31, 2018 , in its Annual Report on Form 10-K filed today with the SEC. Highlights: ZanthoSyn® Sales . Revenues from Cardax's ZanthoSyn®, a physician recommended anti-inflammatory supplement for health...

Cardax to Present at NobleCon XV LEADING SMALL CAP/MICRO CAP CONFERENCE FEATURES >600 ATTENDEES PR Newswire HONOLULU, Jan. 25, 2019 HONOLULU , Jan. 25, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI), a life sciences company focused on inflammatory health, today announced that its CEO, David G. Watumull , will present at NobleCon XV—Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale , Florida—on January 28 th at 11:30 AM Eastern Standard Time . About...

Cardax Reports Q3 2018 Results Robust ZanthoSyn® Sales Growth Continues - 102% Greater Than Q2 2018 - 71% Greater Than Q3 2017 - 129% 9-Month Sales Growth PR Newswire HONOLULU, Nov. 13, 2018 HONOLULU , Nov. 13, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced its results for the third quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased 102% from $272,049 in Q2 2018 to $549,540 in Q3 2018. Q3...

Cardax Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health CHASE Trial to Evaluate Impact of ZanthoSyn® in Largest Astaxanthin Study Ever PR Newswire HONOLULU, Oct. 2, 2018 HONOLULU , Oct. 2, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) has launched its C ardiovascular H ealth A staxanthin S upplement E valuation (CHASE) clinical trial targeting cardiovascular inflammatory health. The first subject was dosed on September 19, 2018 . The randomized, double-blind,...

Cardax Reports Q2 2018 Results ZanthoSyn® Sales 4x Higher Than Q2 2017 PR Newswire HONOLULU, Aug. 13, 2018 HONOLULU , Aug. 13, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) today announced its results for the second quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased more than four times, to $272,049 in Q2 2018 from $66,237 in Q2 2017. Revenues for the six-months ended June 30, 2018 also grew strongly...

Cardax Announces Successful Completion of Warrant Exchange Offer Company Raises $1.44 Million in Non-Dilutive Financing PR Newswire HONOLULU, July 30, 2018 HONOLULU , July 30, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it successfully closed its warrant exchange offer (" Exchange Offer ") on Friday, July 27, 2018 , at 5:00 p.m., Eastern Daylight Time . The Exchange Offer allowed holders of Cardax $0.625 warrants expiring in February 2019 to exchange those warrants,...

Cardax Announces Extension of Warrant Exchange Offer to July 27, 2018 PR Newswire HONOLULU, July 23, 2018 HONOLULU , July 23, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it is extending to July 27, 2018 , the period for its offer (" Exchange Offer ") to allow holders of warrants for its common stock that have an exercise price of $0.625 and expire in February 2019 (" Warrants ") to exchange those Warrants, together with a payment of $0.15 per share, for registered shares...

Cardax Announces Effectiveness of Registration Statement and Commencement of Warrant Exchange Offer PR Newswire HONOLULU, June 22, 2018 HONOLULU , June 22, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that the Securities and Exchange Commission has declared effective the Company's Registration Statement on Form S-4 in connection with a one-time offer to allow holders of its $0.625 warrants expiring in February 2019 to exchange those warrants, together with a payment of $0.15...

Cardax Engages Industry Veteran Fred Sancilio, Ph.D., to Launch Orphan Drug Development Program INFLAMMATION'S MAJOR ROLE IN CHRONIC ORPHAN DISEASES SUPPORTS PROGRAM'S STRONG POTENTIAL PR Newswire HONOLULU, June 13, 2018 HONOLULU , June 13, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it engaged industry veteran and orphan drug expert, Frederick D. Sancilio , Ph.D., to launch the Company's orphan drug development program. Dr. Sancilio has over 40 years of pharmaceutical...

Cardax Reports Q1 2018 Results - ZanthoSyn® Sales Nearly 3-Fold Higher Than Q1 2017 - ZanthoSyn® #1 In Hawaii GNC Stores For Two Quarters In A Row - Accelerating Sales Trend In California And Nevada PR Newswire HONOLULU, May 9, 2018 HONOLULU , May 9, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced its results for the first quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased almost three-fold...

Cardax Announces Warrant Exchange Offer PR Newswire HONOLULU, May 2, 2018 HONOLULU , May 2, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission in connection with a one-time offer to allow holders of its $0.625 warrants expiring in February 2019 to exchange those warrants, together with a payment of $0.15 per share, for registered shares of the Company's common stock. This offer is...

Cardax Reports 2017 Results Strong Revenue Growth in First Full Year of ZanthoSyn® Sales PR Newswire HONOLULU, March 27, 2018 HONOLULU , March 27, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced its results for the year ended December 31, 2017 , the Company's first full year of sales. Revenues from ZanthoSyn ® , its premium astaxanthin dietary supplement for inflammatory health and longevity, increased from $35,258 in 2016—following product launch in August 2016—to $610,323 for...

Cardax Inks Deal to Distribute ZanthoSyn® in China PR Newswire HONOLULU, Feb. 17, 2018 HONOLULU , Feb. 17, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it has signed a Purchase Agreement (the "Agreement") with Health Elite Club Limited ("HECL") of Hong Kong for distribution of ZanthoSyn ® , the Company's premium astaxanthin dietary supplement for inflammatory health and longevity, in China , Hong Kong , Macau , and Taiwan (the "Territories"). HECL is a Hong Kong based...

Cardax Refutes Allegations by Competitive Trade Group, NAXA Cardax also Demands that NAXA Immediately Stop Making "Reckless and Unsupported" Statements that Misinform Consumers and Create Market Confusion PR Newswire HONOLULU, Dec. 5, 2017 HONOLULU , Dec. 5, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) today refuted numerous false and baseless allegations made by the Natural Algae Astaxanthin Association ("NAXA") in a "citizen" petition that it recently filed with the Food and Drug...

Cardax Reports Q3 2017 Results Revenues Up Nearly 5 Times from Q2 2017 PR Newswire HONOLULU, Nov. 14, 2017 HONOLULU , Nov. 14, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced strong ZanthoSyn ® revenues of approximately $322,000 for the third quarter of 2017 — up nearly 5 times from the second quarter of 2017, as reported in the Company's Form 10-Q filed today. These results include the initial national stocking orders of ZanthoSyn from General Nutrition Corporation ("GNC") for its...